Sohini Das
 "Sohini Das")
Sohini Das
Sohini Das leads the automobile and healthcare verticals at Business Standard. In her 17 years as a journalist, she has written on myriad subjects and sectors -- FMCG, dairies, tourism, and state elections, among others, across Kolkata, Ahmedabad and now Mumbai. She loves doing personality stories and ground reportage.
Sohini Das leads the automobile and healthcare verticals at Business Standard. In her 17 years as a journalist, she has written on myriad subjects and sectors -- FMCG, dairies, tourism, and state elections, among others, across Kolkata, Ahmedabad and now Mumbai. She loves doing personality stories and ground reportage.
Page 65 - Sohini Das
Maharashtra CM warns of curbs as Covid case positivity spikes in Mumbai
Meanwhile, the Mumbai civic body has also asked the jumbo Covid centres to be fully staffed and be on a standby
 "Maharashtra CM warns of curbs as Covid case positivity spikes in Mumbai")
Covid endemic, we've to plan how we live with it, says Gagandeep Kang
'Whether we are in the endemic stage depends on how we define endemicity. Covid-19 disease is in the population and would be in the population for a very long time', said Kang
 "Covid endemic, we've to plan how we live with it, says Gagandeep Kang")
Specialty business set to spur growth for Sun Pharma in next 3 yrs: Experts
Global specialty drug sales for Sun Pharma have grown by 39% YoY in FY22 to $674 million
 "Specialty business set to spur growth for Sun Pharma in next 3 yrs: Experts")
From DRL to Glenmark, pharma companies see steady revenue growth in Russia
Strong sales in Q4 during war aided by 'stocking up of inventory'
 "From DRL to Glenmark, pharma companies see steady revenue growth in Russia")
Sun Pharma posts Rs 2,277 cr Q4 loss over settlement of pending US lawsuits
Provides for the settlement charges, says adjusted profit for Q4FY22 at Rs 1582 cr, up 18% YoY after excluding exceptional items of Rs 3,935.7 cr and one-time tax gain of Rs 76.4 cr
 "Sun Pharma posts Rs 2,277 cr Q4 loss over settlement of pending US lawsuits")
Jubilant to double injectable capacity in US at a cost of $193 mn
Signs agreement with US biomedical dept
 "Jubilant to double injectable capacity in US at a cost of $193 mn")
Serum Institute likely to launch cervical cancer vaccine in India in Nov
Country now depends on foreign companies and Serum's product is likely to bring down prices.
 "Serum Institute likely to launch cervical cancer vaccine in India in Nov")
Board evaluating Sebi penalty of Rs 1 crore, says Fortis Healthcare
Market regulator SEBI slapped a fine on Fortis Healthcare subsidiaries on account of fund diversion by erstwhile promoters
 "Board evaluating Sebi penalty of Rs 1 crore, says Fortis Healthcare")
Dr Reddy's Labs Q4 PAT falls 76% on pricing pressure, low export benefit
Dr Reddy's Q4 results: The revenue was up 15% to Rs 5,437 crore for the quarter under review
 "Dr Reddy's Labs Q4 PAT falls 76% on pricing pressure, low export benefit")
Dr Reddy's plans new brands in Russia, says no issue with funds in country
The company's Russian revenue was at Rs 686 crore for Q4FY22, a year-on-year growth of 70%.
 "Dr Reddy's plans new brands in Russia, says no issue with funds in country")
Madurai to Agra, smaller towns witness strong growth in sales of medicines
In terms of launches, around 68% have been in acute therapy in last 12 months, data shows
 "Madurai to Agra, smaller towns witness strong growth in sales of medicines")
India-developed 'variant-proof' Covid vaccine likely in 2-3 years: Industry
Domestically produced variant-proof jabs are part of a global project to develop vaccines for future epidemics
 "India-developed 'variant-proof' Covid vaccine likely in 2-3 years: Industry")
Adani Group enters healthcare, will set up medical and research facilities
A subsidiary called Adani Health Ventures will commence its business operations in 'due course', says conglomerate.
 "Adani Group enters healthcare, will set up medical and research facilities")
India likely to extend credit line to Sri Lanka for essential medicines
The quantum of the line of credit to be extended is not yet known
 "India likely to extend credit line to Sri Lanka for essential medicines")
Lupin logs net loss of Rs 512 cr in Q4 on rising costs, impairment expense
Quarter was challenging due to 'headwinds in the US on account of price erosion', says company.
 "Lupin logs net loss of Rs 512 cr in Q4 on rising costs, impairment expense")
How Prathap Chandra Reddy propelled Apollo Hospitals into a new orbit
The struggle that he went through in setting up a private health care facility in the India of the 1980s is part of folklore
 "How Prathap Chandra Reddy propelled Apollo Hospitals into a new orbit")
We aim to test 500,000 patients a day in 5 years: Dr Lal PathLabs CMD
Dr Lal PathLabs is India's largest diagnostic services player by revenue, with 289 laboratories across the country
 "We aim to test 500,000 patients a day in 5 years: Dr Lal PathLabs CMD")
Caring for patients runs in our DNA, say Cipla's Samina Hamied, Umang Vohra
'Cipla has so many capabilities that for anything we need to do, we say we can do it'
 "Caring for patients runs in our DNA, say Cipla's Samina Hamied, Umang Vohra")
Rejuvenating Cipla: After global expansion, acquisitions on cards
Having consolidated its presence across geographies, the pharma major is looking at acquisitions
Sun Pharma to launch new oral lipid lowering drug under Brillo brand
Claims drug has a new mechanism of action compared to currently available lipid lowering agents, is indicated for people with inherited genetic disorder
 "Sun Pharma to launch new oral lipid lowering drug under Brillo brand")
